649 related articles for article (PubMed ID: 16791599)
1. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Galvin JE
Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
[TBL] [Abstract][Full Text] [Related]
2. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
4. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
Maingay M; Romero-Ramos M; Carta M; Kirik D
Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
[TBL] [Abstract][Full Text] [Related]
5. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
6. Dopamine D2 receptor knockout mice develop features of Parkinson disease.
Tinsley RB; Bye CR; Parish CL; Tziotis-Vais A; George S; Culvenor JG; Li QX; Masters CL; Finkelstein DI; Horne MK
Ann Neurol; 2009 Oct; 66(4):472-84. PubMed ID: 19847912
[TBL] [Abstract][Full Text] [Related]
7. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation.
Leong SL; Pham CL; Galatis D; Fodero-Tavoletti MT; Perez K; Hill AF; Masters CL; Ali FE; Barnham KJ; Cappai R
Free Radic Biol Med; 2009 May; 46(10):1328-37. PubMed ID: 19248830
[TBL] [Abstract][Full Text] [Related]
8. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
9. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.
Burke WJ; Li SW; Williams EA; Nonneman R; Zahm DS
Brain Res; 2003 Nov; 989(2):205-13. PubMed ID: 14556942
[TBL] [Abstract][Full Text] [Related]
10. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
[TBL] [Abstract][Full Text] [Related]
11. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
12. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra.
Mori F; Nishie M; Kakita A; Yoshimoto M; Takahashi H; Wakabayashi K
J Neuropathol Exp Neurol; 2006 Aug; 65(8):808-15. PubMed ID: 16896314
[TBL] [Abstract][Full Text] [Related]
13. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
15. Dopamine complexes of iron in the etiology and pathogenesis of Parkinson's disease.
Arreguin S; Nelson P; Padway S; Shirazi M; Pierpont C
J Inorg Biochem; 2009 Jan; 103(1):87-93. PubMed ID: 18976814
[TBL] [Abstract][Full Text] [Related]
16. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
[TBL] [Abstract][Full Text] [Related]
17. Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells.
Yamakawa K; Izumi Y; Takeuchi H; Yamamoto N; Kume T; Akaike A; Takahashi R; Shimohama S; Sawada H
Biochem Biophys Res Commun; 2010 Jan; 391(1):129-34. PubMed ID: 19900407
[TBL] [Abstract][Full Text] [Related]
18. Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.
Shimoji M; Zhang L; Mandir AS; Dawson VL; Dawson TM
Brain Res Mol Brain Res; 2005 Mar; 134(1):103-8. PubMed ID: 15790534
[TBL] [Abstract][Full Text] [Related]
19. Toxic effects of dopamine metabolism in Parkinson's disease.
Hattoria N; Wanga M; Taka H; Fujimura T; Yoritaka A; Kubo S; Mochizuki H
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S35-8. PubMed ID: 19131041
[TBL] [Abstract][Full Text] [Related]
20. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine.
Burke WJ; Kumar VB; Pandey N; Panneton WM; Gan Q; Franko MW; O'Dell M; Li SW; Pan Y; Chung HD; Galvin JE
Acta Neuropathol; 2008 Feb; 115(2):193-203. PubMed ID: 17965867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
